We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study / Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:12(2007), pp. 1721-1722. [10.3324/haematol.11345]

Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study

Candoni A.;
2007-01-01

Abstract

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.
92
12
1721
1722
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian multicentric phase II study / Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 92:12(2007), pp. 1721-1722. [10.3324/haematol.11345]
Piccaluga, P. P.; Malagola, M.; Random, M.; Arpinati, M.; Paolini, S.; Candoni, A.; Fanin, R.; Messa, E.; Pirrotta, M. T.; Lauria, F.; Visant, G.; Albert, D.; Rancati, F.; Vinaccia, V.; Russo, D.; Saglio, G.; Baccarani, M.; Martinelli, G.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1294021
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact